Pyrazinamide clinical pharmacology: Difference between revisions
Created page with "__NOTOC__ {{Pyrazinamide }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIK..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pyrazinamide }} | {{Pyrazinamide}} | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Clinical Pharmacology== | |||
Pyrazinamide is well absorbed from the GI tract and attains peak plasma concentrations within 2 hours. Plasma concentrations generally range from 30 to 50 mcg/mL with doses of 20 to 25 mg/kg. It is widely distributed in body tissues and fluids including the liver, lungs and cerebrospinal fluid (CSF). The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges.1 Pyrazinamide is approximately 10% bound to plasma proteins.2 The half-life (t 1/2) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function. The plasma half-life may be prolonged in patients with impaired renal or hepatic function. Pyrazinamide is hydrolyzed in the liver to its major active metabolite, pyrazinoic acid. Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid.3 | |||
Approximately 70% of an oral dose is excreted in the urine, mainly by glomerular filtration within 24 hours.3 | |||
Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection. The mechanism of action is unknown. In vitro and in vivo the drug is active only at a slightly acidic pH.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a719ec72-771f-49c9-b93d-9d5f585176a4 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a719ec72-771f-49c9-b93d-9d5f585176a4 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 02:56, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Clinical Pharmacology
Pyrazinamide is well absorbed from the GI tract and attains peak plasma concentrations within 2 hours. Plasma concentrations generally range from 30 to 50 mcg/mL with doses of 20 to 25 mg/kg. It is widely distributed in body tissues and fluids including the liver, lungs and cerebrospinal fluid (CSF). The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges.1 Pyrazinamide is approximately 10% bound to plasma proteins.2 The half-life (t 1/2) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function. The plasma half-life may be prolonged in patients with impaired renal or hepatic function. Pyrazinamide is hydrolyzed in the liver to its major active metabolite, pyrazinoic acid. Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid.3
Approximately 70% of an oral dose is excreted in the urine, mainly by glomerular filtration within 24 hours.3
Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection. The mechanism of action is unknown. In vitro and in vivo the drug is active only at a slightly acidic pH.[1]
References
Adapted from the FDA Package Insert.